While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...
Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...
As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...
AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...
Nektar Therapeutics has presented data of its atopic dermatitis (AD) candidate rezpeg (rezpegaldesleukin), which sent the ...
Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.
Reduced demand from international markets and increased regulatory complexity are among the challenges that tariffs are ...
Trially has raised $4.7m in a seed funding round and introduced its agentic AI solution, Margo, designed to increase study ...
Johnson & Johnson said the combination was investigated in 49 patients with newly diagnosed multiple myeloma. Image credit: PixelBiss / Shutterstock.com Johnson & Johnson’s (J&J’s) multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback